Table 2.
Summary of pooled results of primary and sensitivity analyses
| Pooled results | ||||
|---|---|---|---|---|
| Analysis | All trialsa | Surgical patient subgroup | Medical patient subgroup | P valueb |
| Primary | ||||
| Trials included in more recent review [2]c | 0.93 (0.84 to 1.04, P = 0.20), I2 = 45% (2 to 69%); 26 trials; 13,549 patients |
0.85 (0.69 to 1.04, P = 0.11), I2 = 51% (1 to 75%); 18 trials; 6,164 patients |
1.02 (0.95 to 1.09, P = 0.61), I2 = 0% (0 to 41%); 18 trials; 7,113 patients |
0.10 |
| Sensitivity | ||||
| Only mixed ICU trials enrolling both surgical and medical patients | 0.97 (0.85 to 1.11, P = 0.66), I2 = 54% (0 to 79%); 14 trials; 10,121 patients |
0.98 (0.80 to 1.19, P = 0.82), I2 = 40% (0 to 75%); 12 trials; 4,137 patients |
1.03 (0.94 to 1.13, P = 0.51), I2 = 8% (0 to 62%); 12 trials; 5,722 patients |
0.66 |
| Incorporating additional trials included in earlier review [1] | 0.96 (0.87 to 1.06, P = 0.43), I2 = 36% (0 to 61%); 32 trials; 15,051 patients |
0.89 (0.74 to 1.08, P = 0.24), I2 = 45% (0 to 71%); 21 trials; 6,644 patients |
1.02 (0.96 to 1.09, P = 0.46), I2 = 0% (0 to 31%); 21 trials; 8,135 patients |
0.18 |
| Only trials achieving mean blood glucose 4.4 to 6.1 mM in IIT group | 0.80 (0.60 to 1.07, P = 0.14), I2 = 43% (0 to 76%); 12 trials; 2,879 patients |
0.76 (0.57 to 1.01, P = 0.06), I2 = 10% (0 to 68%); 9 trials; 2,474 patients |
1.04 (0.71 to 1.53, P = 0.82), I2 = 7% (0 to 76%); 6 trials; 289 patients |
0.20 |
Data presented as risk ratio (95% confidence interval). I2, percentage of total variation across studies due to between-study heterogeneity rather than chance; ICU, intensive care unit; IIT, intensive insulin therapy. aIncludes also mixed ICU trials for which separate surgical and medical subgroup data were not available [19,20]. bSurgical versus medical interaction. cSee also Figure 1.